*Third party registration should be used if you are requesting an individual registration for someone who is not you.
Please note that website registration under your name will be needed before registering someone else to this event.
M.S. Aapro, CH - J. Gligorov, FR
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This course aims to take stock of current and future tools that help us optimize the care of patients with breast cancer.
- Improve breast cancer patients care: value and clinical utility of prediction of CT benefit for early stage breast cancer patients
- Practicing through case discussions
Under the auspices of
Matti Aapro, Clinique de Genolier, Breast Center, Genolier, CH
Fabrice André, Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, FR
Anna Batistatou, University of Ioannina, Faculty of Medicine, Ioannina, GR
Francesco Cognetti, Istituto Nazionale Tumori Regina Elena, Dipartimento di Oncologia Medica, Roma, IT
Joseph Gligorov, University Cancer Institute APHP.6 Sorbonne University, Breast Cancer Expert Center, Paris, FR
Susan Knox, Europa Donna - The European Breast Cancer Coalition, Milan, IT
Christos Markopoulos, Athens, GR
Riccardo Masetti, Università Cattolica di Roma, Oncology Dpt., Roma, IT
Belinda Nedjai, Queen Mary University of London, Wolfson Institute of Preventive Medicine - Centre for Cancer Prevention, London, GB
Frederique Penault Llorca, Centre Jean Perrin, Anatomopathology Dpt., Clermont-ferrand Cedex, FR
Giancarlo Pruneri, Fondazione IRCCS - Istituto Nazionale dei Tumori, Pathology Dpt., Milano, IT
Pascale Pujol, Centre Hospitalier Universitaire de Montpellier, Genetics Department, Montpellier Cedex5, FR
Elzbieta Senkus, Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, PL
Zsuzsanna Varga, University Hospital Zurich, Pathology Dept., Zurich, CH
Mark Verrill, Northern Centre for Cancer Care, Freeman Hospital, Medical Oncology Dept., Newcastle upon Tyne, GB
Sharing Progress in Cancer Care
Piazza Indipendenza, 2
6500 Bellinzona – Switzerland
Luis.email@example.com - Tel: +41 91 820 09 58
Mercure Roma West
Via Eroi di Cefalonia, 301
Phone: +39 06 50 83 41 11
CME Accreditation and Certificates
Participants will be entitled to receive a certificate of attendance at the close of the event by completing the on-line evaluation questionnaire.
Application for CME recognition will be submitted to the Accreditation Council of Oncology in Europe (ACOE) and the European Accreditation Council for Continuing Medical Education (EACCME), an institution of the European Union of Medical Specialists (UEMS).
EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA).
Information on the status of the applications can be obtained from the organising secretariat.
Sharing Progress in Cancer Care wishes to extend its appreciation to Exact Sciences for having granted its participation and support to the Course.
Travel grants are made available on a competitive basis.
Full applications should be submitted by 28 June 2020 via website www.spcc.net.
- Curriculum vitae including full affiliation, contact details and date of birth;
- Letter describing motivation for attending;
- Letter of endorsement by the Institute/Department director.
Travel grant recipients will receive a set amount to contribute to their travel expenses, whilst registration ad accommodation will be processed directly by SPCC.
The following amounts will be refunded by bank transfer after the Course:
The outcome of the application will be notified by 22 July.
Terms and Conditions
All rates are quoted in Euro and include VAT.
• 2 nights accommodation at the venue
• Participation in all sessions and a copy of the Programme Book,
• Coffee breaks and lunches as indicated in the programme.
CANCELLATION OF REGISTRATION OR REPLACEMENT
Cancellation should be notified to SPCC in writing. In case of cancellation without replacement, the fee less handling charges of EUR 100 will be refunded within two months from notification, provided that the cancellation is received by SPCC before 13 September 2020. Replacements will be possible till 20 September 2020.
CONFIRMATION OF REGISTRATION
Registration will be confirmed by e-mail.
The badge is the only official evidence of registration and should be worn at all times during the event. Loss of badge causes loss of registration.
The organisers bear no responsibility for untoward events in relation to the participation in the course. Participants are advised to take out their own personal and travel insurance.
|9:00||Welcome and introduction |
Matti Aapro, CH - Joseph Gligorov, FR
|9:15||Optimize patient management in breast cancer: guiding adjuvant treatment decisions |
Mark Verrill, GB
|9:40||Clinical utility of multigene assays in early breast cancer|
|9:40||Predictive tests |
Christos Markopoulos, GR
|9:55||Prognostic tests |
Francesco Cognetti, IT
|10:45||Who to test with multigene assay: treatment algorithms – specific patient profiles (lobular; premenopausal CT decisions)|
|11:00||Next Generation Sequencing . The Pathology perspective |
Anna Batistatou, GR
|11:30||Roundtable: Evidence based assessment of diagnostic tests: criteria for a health technology assessment – why outcomes of HTA decisions can be different…?|
|11:30||The French rationale |
Pascale Pujol, FR
|11:40||Why NICE accepted? |
Mark Verrill, GB
|11:50||Why German authorities accepted?|
|12:15||The patient’s perspective: patient preferences, patient journey |
Susan Knox, IT
|14:15||Group session: Patient Case discussion on multigene assays in early breast cancer: who to test and how to deal with the results?|
|Case 1: 1 patient 29 years luminal pN0 with low risk signature results|
|Case 2: 1 patient 73 years luminal pN1 with high risk signature results|
|Case 3: 1 patient 45 years luminal pN0 with intermediate risk signature results|
|Case 4: 1 patient 52 years luminal pN0 with intermediate risk signature|
|Group 1 |
Panellists: Joseph Gligorov, FR - Riccardo Masetti, IT - Elzbieta Senkus, PL
|Group 2 |
Panellists: Matti Aapro, CH - Christos Markopoulos, GR - Giancarlo Pruneri, IT
|8:30||DNA Methylation |
Belinda Nedjai, GB
|9:00||NGS impact or not in breast cancer |
Fabrice André, FR
|9:30||Alpelisib what to test |
Frederique Penault Llorca, FR - Elzbieta Senkus, PL
|10:00||Parp inhibitors what to test |
Pascale Pujol, FR
|11:00||Immunotherapy: what to test |
Francesco Cognetti, IT - Frederique Penault Llorca, FR
|11:40||New definition of ASCO CAP HER-2 positivity |
Joseph Gligorov, FR - Frederique Penault Llorca, FR
Matti Aapro, CH - Joseph Gligorov, FR
|12:35||Lunch and departures|